Alzheimer's disease, a multifactorial disorder seeking multitherapies
Khalid Iqbal1, Inge Grundke-Iqbal
1New York State Institute for Basic Research In Developmental Disabilities, Staten Island, NY, USA. khalid.iqbal.ibr@gmail.com
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|September 4, 2010
Summary
Alzheimer's disease (AD) involves multiple mechanisms, with at least five subgroups identified by cerebrospinal fluid markers. Stratifying patients by these Alzheimer's disease subgroups is crucial for developing effective treatments.
Area of Science:
- Neurology
- Biochemistry
- Pharmacology
Background:
- Alzheimer's disease (AD) is a complex neurodegenerative disorder with multifactorial etiopathogenesis.
- Existing research suggests at least five distinct AD subgroups based on cerebrospinal fluid (CSF) biomarker levels.
Purpose of the Study:
- To highlight the importance of identifying AD subgroups for targeted therapeutic development.
- To emphasize the role of CSF biomarkers in stratifying patients and monitoring treatment efficacy.
Main Methods:
- Analysis of cerebrospinal fluid (CSF) levels of key biomarkers.
- Identification of Alzheimer's disease (AD) subgroups based on Abeta(1-42), tau, and ubiquitin levels.
Main Results:
- Demonstrated the existence of at least five distinct Alzheimer's disease (AD) subgroups.
- Confirmed CSF biomarker levels (Abeta(1-42), tau, ubiquitin) as reliable indicators for subgroup identification.
Conclusions:
- Stratifying Alzheimer's disease (AD) patients into subgroups is essential for clinical trials.
- Tailored therapeutic strategies targeting specific AD subgroups may improve treatment outcomes.
- CSF biomarkers are critical for both AD patient stratification and response monitoring to novel drugs.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.